Find policies, billing codes, payers, states, and providers
Cell‑Free Fetal DNA Testing
Customize your policy alerts
Sign up for UnitedHealthcare Policy CSO85.AE alerts
Get alerted when Policy CSO85.AE changes without checking for updates manually.
Monitor payer policy activity
Governs medical necessity and coverage of cell‑free fetal DNA testing (noninvasive prenatal testing), including aneuploidy screening and RhD/fetal genotype testing; excludes expanded indications and lists state‑specific applicability.
Added language that cfDNA testing using maternal plasma to determine fetal genotype is proven and medically necessary when the individual is alloimmunized or at risk for alloimmunization and all specified conditions are met.
Removed language listing multiple common clinical indications (including maternal age ≥35, abnormal ultrasound, prior trisomy, positive serum screen, translocation, post-counseling screening) as proven and medically necessary indications for cfDNA aneuploidy screening.
Replaced broad 'unproven and not medically necessary for all other indications' statement with a narrower statement that cfDNA using maternal plasma is unproven and not medically necessary for indications beyond screening for trisomies 21, 18, 13, and sex.
Cell-Free Fetal DNA testing using maternal plasma to determine fetal genotype is proven and medically necessary when the individual undergoing testing is alloimmunized or at risk for alloimmunization due to maternal RhD status or the presence of red cell antigen antibodies, and all of the following: paternal genotyping shows heterozygosity for RhD or paternal RhD status is unknown and indicated invasive diagnostic testing for fetal genotyping has been offered and declined.
Language indicating DNA-based noninvasive prenatal tests of fetal Aneuploidy are proven and medically necessary as screening tools for trisomy 21, 18, or 13, with or without fetal sex chromosomes, for specified high-risk indications (e.g., maternal age ≥35, ultrasound findings, prior trisomy, positive serum screen, parental translocation, after pre-test counseling).
Cell-Free Fetal DNA testing using maternal plasma is considered unproven and not medically necessary for indications beyond screening for trisomies 21, 18, 13, and sex chromosome aneuploidy, and expanded panel testing beyond those is listed as unproven.
Removed multiple definitions (e.g., Mosaicism, MPS, NGS, SNPs, SDM, trisomy definitions) and removed many listed ICD-10 diagnosis codes and some CPT codes (0327U, 81420, 81507).
Coverage Criteria — When cfDNA Testing Is Covered
Medically necessary: cfDNA for fetal genotyping in alloimmunized or at-risk pregnancies
Cell-free fetal DNA testing using maternal plasma is considered medically necessary for fetal genotyping in alloimmunized or at-risk pregnancies when ALL of the following are met:
Support with maternal antibody status; aligns with policy coverage rationale.
Document that invasive diagnostic testing was offered and declined as a condition of noninvasive cfDNA coverage.
One of these paternal genotype conditions must be met per coverage rationale.
Expanded cfDNA screening — conditional coverage guidance
Covered when ALL of the following are met (conditional guidance reflecting limited PPV, need for counseling, and requirement for diagnostic confirmation):
Reflects synthesis of systematic reviews and society guidance about counseling and PPV.
Based on evidence of low PPV and recommendations for diagnostic confirmation.
Limited to situations where clinical suspicion justifies expanded analysis per included studies.
Reflects the conditional nature of coverage and counseling requirements noted in evidence syntheses.
Professional Society Guidance
Relevant professional society recommendations and policy-relevant conclusions from cited studies:
Summary of ACMG guidance from the policy.
Reflects ACOG practice bulletin and clinical practice update statements.
Captures society-level cautions and recommended management pathways.
Fetal antigen testing (alloimmunization)
Covered when ALL of the following are met for fetal antigen testing related to alloimmunization (per ACOG practice update and validation studies):
ACOG practice update supports cfDNA as a reasonable alternative to invasive testing when declined.
Reflects published validation results and caution about outcome data.
Operational note consistent with professional guidance and policy documentation requirements.
Emerging applications (CNV, microdeletions, single-gene)
Not routinely covered / informational: cfDNA for CNV/microdeletion beyond 22q11.2, general population single‑gene disorder screening, and other subchromosomal detection — evidence is preliminary and limited:
Cites variable performance and low‑quality evidence described in multiple studies.
Reflects study findings and ACOG practice advisory cautioning against routine single‑gene cfDNA screening.
Fetal genotype cfDNA testing for alloimmunized or at-risk pregnancies (Proven / Medically Necessary)
Covered when ALL of the following are met:
Foundation of the proven indication per policy history.
One of these paternal conditions must be true per coverage rationale.
Policy requires documentation that invasive diagnostic testing was offered and declined before noninvasive cfDNA is covered.
cfDNA for common autosomal aneuploidies and sex (Covered with counseling / screening context)
Covered as screening for trisomy 21, trisomy 18, trisomy 13, and sex chromosomes when appropriate counseling is provided; diagnostic testing should be offered to confirm positive screening results.
Emphasizes counseling, single‑screen approach, and that cfDNA is not diagnostic.
Consistent with ACOG/ISPD recommendations.
Fetal RhD/genotype testing - Medically Necessary
Covered when ALL of the following are met for fetal RhD/genotype testing:
Documentation should support maternal antibody status.
One of these paternal genotype conditions must be met.
Document offer and declination; supports prior authorization and medical record requirements.
Aneuploidy screening (trisomy 21, 18, 13, sex chromosomes)
Covered when meeting policy screening scope:
Other previously listed high‑risk indications were removed from the proven list; screening scope retained for core conditions.
Cell-free fetal DNA (cfDNA) testing is considered unproven and not medically necessary for indications beyond screening for trisomies 21, 18, 13, and sex chromosome aneuploidy. Explicit exclusions include testing solely to determine twin zygosity, expanded panel testing that includes targets beyond the core aneuploidies/SCA, genome- or exome-wide screening (for example, MaterniT® Genome), and routine screening for microdeletions/microduplications/CNVs or other rare aneuploidies because current evidence shows limited clinical validation and a high rate of false positives.
Use of cfDNA for prenatal exome or genome sequencing and routine population screening for microdeletions or CNVs is not supported by current evidence and is excluded from standard coverage pending further validation. Systematic and clinical utility evaluations report low-quality evidence, high false positive rates in some series, and insufficient data to demonstrate improvement in clinical outcomes from routine genome-wide CNV screening.
Routine cfDNA screening for copy number variants other than 22q11.2 and routine single-gene cfDNA screening for the general population are not recommended. Professional guidance notes limited validation for CNV and microdeletion screening beyond 22q11.2 and advises against expanding NIPT to report microdeletions broadly; similarly, single-gene cfDNA approaches remain investigational for population-wide screening due to insufficient evidence of accuracy and predictive value.
cfDNA testing is considered unproven for expanded indications beyond screening for the core trisomies and fetal sex—this includes routine genome-wide CNV screening, broad microdeletion panels, and widespread reporting of rare autosomal trisomies. Professional societies emphasize that expanded genome-wide approaches have not been clinically validated and that positive screening results require confirmatory diagnostic testing before management decisions.
Expanded panel testing and other non-core indications (for example, panels that add targets beyond trisomies 21, 18, 13, and sex chromosomes) are listed as unproven and not medically necessary. The policy explicitly excludes routine fetal antigen testing other than RhD, genome- or exome-wide screening, and tests performed solely to determine fetal sex unless sex determination is essential for diagnosis.
Summary exclusions include: expanded panels (beyond trisomies 21/18/13 and sex), genome-wide or exome-wide prenatal screening, routine microdeletion/CNV screening (except limited consideration for 22q11.2 in some guidance), and fetal antigen testing other than RhD. These applications lack sufficient evidence of clinical utility and are not covered for routine use.
Evidence is insufficient to support routine screening of average-risk pregnancies for rare autosomal trisomies (RATs) or broad genome-wide CNV/microdeletion panels. Large cohort and clinical utility evaluations have found low positive predictive values and high false positive rates for these expanded indications, indicating limited benefit and potential harms from unnecessary confirmatory procedures.
Screening by cfDNA to evaluate single-gene disorders is considered investigational for general population use. Early studies show promise in selected, high-risk cohorts, but available data are limited by small sample sizes, incomplete outcome verification, and lack of broad validation; professional guidance does not endorse routine single-gene cfDNA screening for all pregnant individuals.
Routine use of cfDNA for single-gene disorders, genome-wide CNV or microdeletion screening, or other expanded NIPT beyond trisomies 21/18/13 and sex is unproven. Major professional statements caution against expanding NIPT reporting to microdeletions or broad genomic findings because predictive values are low in general-risk populations and confirmatory diagnostic testing remains necessary for any positive result.
Exceptions and non-covered uses summarized: requests for cfDNA testing for aneuploidies beyond trisomies 21, 18, 13 and sex, expanded panels that add microdeletions/CNVs or other targets, and fetal antigen testing other than RhD are considered unproven and not medically necessary and may be denied. Additional listed noncovered indications include testing solely for fetal sex, pregnancies with ≥3 fetuses, repeat testing for low fetal fraction, vanishing twin, and missed abortion/fetal demise.
Coding — Procedure and Diagnosis Codes
| 0060U | Twin zygosity, genomic targeted sequence analysis of chromosome 2, using circulating cell-free fetal DNA in maternal blood. |
| 0488U | Obstetrics (fetal antigen noninvasive prenatal test), cell-free DNA sequence analysis for detection of fetal presence or absence of 1 or more of the Rh, C, c, D, E, Duffy (Fya); or Kell (K) antigen in alloimmunized pregnancies; reported as selected antigen(s) detected or not detected. |
| 0489U | Obstetrics (single-gene noninvasive prenatal test), cell-free DNA sequence analysis of 1 or more (HBB, HBA1, HBA2) to identify paternally inherited pathogenic variants, and relative mutation-dosage analysis based on molecular counts to determine fetal inheritance of maternal mutation. |
| 0494U | Red blood cell antigen (fetal RhD analysis), next-generation sequencing of circulating cell-free DNA (cfDNA) of blood in pregnant individuals known to be RhD negative, reported as positive or negative gene. |
| 0536U | Red blood cell antigen (fetal RhD), PCR analysis of exon 4 of RHD gene and housekeeping control gene GAPDH from whole blood in pregnant individuals at 10+ weeks gestation known to be RhD negative, reported as fetal RhD status. |
| 81422 | Fetal chromosomal microdeletion(s) genomic sequence analysis, circulating cell-free fetal DNA in maternal blood. |
| 81479 | Unlisted molecular pathology procedure. |
| 099.210 | ICD-10 code listed in Applicable Codes |
| Z36.2 | ICD-10 code listed in Applicable Codes |
Provider Actions — Prior Authorization, Documentation, and Follow-up
Prior Authorization Required for Listed cfDNA Codes
Prior authorization is required for the listed cfDNA testing codes. Submit PA before testing to avoid claim denials.
- Prior authorization required for listed cfDNA CPT/HCPCS and proprietary codes prior to service.
- Verify member eligibility and PA requirements with UnitedHealthcare prior to ordering.
Prior Authorization for Expanded cfDNA Testing
Prior authorization is required for expanded cfDNA testing beyond standard aneuploidy screening. Tests for CNVs, microdeletions, prenatal exome/genome, single-gene cfDNA, or other expanded indications require PA and are subject to evidentiary review.
- Expanded cfDNA tests (e.g., NIPT-plus, CNV screening, prenatal exome/genome, single-gene panels) require prior authorization and documentation of medical necessity.
- Coverage for expanded indications is limited and may be denied if evidence is insufficient.
Prior Authorization Note for Fetal Antigen Testing
Prior authorization is required for fetal antigen (RhD and selected non‑RhD) cfDNA testing in alloimmunized pregnancies. PA must document that invasive diagnostic testing was offered and declined when applicable.
Verify Coding and Prior Authorization
Verify coding and prior authorization requirements before submitting claims. Using incorrect codes or omitting a required PA may result in claim denial or delay.
- Confirm the exact CPT/HCPCS or proprietary code to be billed against the member's plan.
- Confirm PA has been approved for the specific code(s) and indication prior to testing.
Insufficient Evidence May Trigger Denial
Insufficient or low-quality evidence for many expanded cfDNA indications may result in denial of coverage. Requests for screening beyond established aneuploidy and select alloimmunization uses are subject to denial.
- Requests for microdeletion, CNV, prenatal exome/genome, single‑gene cfDNA or other unproven indications may be denied due to insufficient evidence.
- Denial may be issued when medical records do not support the requested indication or when confirmatory diagnostic testing is not offered or documented.
Denial Risk for Unproven Indications
Tests for unproven cfDNA indications are at risk for denial. Document clinical rationale and supporting literature when requesting coverage for indications outside established criteria.
- Unproven indications include (but are not limited to): routine population screening for microdeletions, broad CNV screening, prenatal exome/genome, and many single‑gene screens.
- Provide detailed clinical justification and prior authorization to reduce risk of denial.
Required Clinical Information at Time of Testing
Provide required clinical information at the time of testing and/or prior authorization to support medical necessity. Incomplete documentation may delay review or result in denial.
- Indication for testing and relevant clinical history (e.g., alloimmunization status, prior pregnancy with aneuploidy, ultrasound findings).
- Gestational age at time of draw, maternal age/weight if requested by lab, paternal genotype where relevant.
- Documentation that invasive diagnostic testing (amniocentesis/CVS) was offered and declined when cfDNA is used as an alternative for fetal genotyping.
Documentation Needed for Fetal Genotype cfDNA in Alloimmunization
For fetal genotype cfDNA testing in alloimmunized pregnancies, document: maternal antibody specificity and titers, paternal genotype or zygosity results (if available), that invasive diagnostic testing was offered and declined (if applicable), and how results will affect pregnancy management.
- Include maternal alloimmunization details (antibody type, clinically significant titers) and prior pregnancy history.
- If paternal genotyping shows heterozygosity or is unknown, document rationale for fetal cfDNA testing.
- Document planned follow-up and management steps based on potential cfDNA results.
Use of cfDNA When Invasive Testing Declined
cfDNA may be used when invasive diagnostic testing is declined by the patient, but documentation that CVS/amniocentesis were offered and declined is required for coverage considerations.
- Document that invasive diagnostic procedures were discussed/offered and that the patient declined.
- When cfDNA is used as an alternative, include documentation of informed shared decision‑making regarding risks, benefits, and limitations.
Use of cfDNA as Secondary Screen
cfDNA can be used as a secondary (contingent) screening option following a positive serum‑based screen in patients wishing to avoid diagnostic testing; PA and documentation of the initial positive screen and counseling should be provided.
- Document initial positive serum screening results and that patient opts for cfDNA instead of invasive diagnostic testing.
- Ensure a single screening approach is followed per ACOG guidance — avoid simultaneous multiple screening tests without clear rationale.
Background and Evidence Context
Background: Cell-free fetal DNA (cffDNA) are placental DNA fragments circulating in maternal blood that can be analyzed noninvasively beginning at about 10 weeks' gestation. cffDNA testing can screen for common fetal aneuploidies (trisomies 21, 18, 13) and sex chromosome aneuploidies and may determine fetal RhD status, but results are screening-level and invasive diagnostic testing (CVS or amniocentesis) is required to confirm positive findings before making irreversible clinical decisions.
Definitions and Key Terms
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.